Anti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed/relapsed after CART19/20 therapy

CD19-directed chimeric antigen receptor T cell (CART19) therapy is efficient and approved for relapsed/refractory diffuse large B cell lymphoma (DLBCL). To increase durable antitumor response, we previously designed tandem CART19/20 cells and shown longer progression-free survival. However, a propor...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Chunmeng, Shi, Fengxia, Liu, Yang, Zhang, Yajing, Dong, Liang, Li, Xiang, Tong, Chuan, Wang, Yao, Su, Liping, Nie, Jing, Han, Weidong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8259370/
https://www.ncbi.nlm.nih.gov/pubmed/34225766
http://dx.doi.org/10.1186/s13045-021-01120-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8259370/
https://www.ncbi.nlm.nih.gov/pubmed/34225766
http://dx.doi.org/10.1186/s13045-021-01120-3

Ejemplares similares